NCE-1 Intelligence & Market Opportunity

Rivfloza

Nedosiran

Antimetabolic Disorder

Injection

Rivfloza is a once-monthly injection for children more than 2 years old and adults with primary hyperoxaluria type 1. It lowers urine oxalate levels by silencing a liver enzyme, helping protect kidney function.

Approval Date

29-Sep-23

NCE-1 Date

29-Sep-27

NCE Date

29-Sep-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

108

2028

129

2029

142

2030

150

2031

161

2032

172

Molecule profile

Details & specifications

Molecule

Nedosiran

Innovator

NOVO NORDISK INC

Dosage Form

Injection

Strength

80 mg base/0.5 mL, 128 mg base/0.8 mL, 160 mg base/1 mL

Therapeutic Category

Antimetabolic Disorder

Usage

To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.